Effect of basal insulin supplement therapy on diabetic retinopathy in short-duration type 2 diabetes: A one-year randomized parallel-group trial

What Was Tested

Researchers studied Insulin Glargine in the context of diabetic retinopathy and glaucoma in this randomized controlled trial publication.

In this study, the researchers compared the effect on diabetic retinopathy (DR) between oral antidiabetic drugs (OADs) alone and in combination with basal insulin-supported OADs therapy (BOT). [Correction added on 11 November 2019, after first online publication: In Abstract under Background section, "DR" has been corrected into "diabetic retinopathy (DR)".] METHODS: Between January 2015 and January 2018, this study enrolled 290 patients (age 18-65 years) with diabetes duration between 0 and 5 years.

Patients were randomly assigned to receive OADs or BOT after 14 days intensive insulin treatment.

Who Took Part

The study group was 290 patients.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

The methods mention a period of 14 days.

What Was Measured

The subject headings attached to it are Biomarkers, Blood Glucose, China, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Glycated Hemoglobin and Hypoglycemic Agents.

The authors tagged it with the keywords basal insulin, glycemic variability, subsequent therapy, 后续治疗, 基础胰岛素 and 糖尿病视网膜病变.

What This Means in Plain Language

The paper is a randomized study of Insulin Glargine in 290 patients in people with diabetic retinopathy and glaucoma over 14 days.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Journal of diabetes), a journal based in Australia.

More context: the Insulin Glargine compound page, Diabetic retinopathy and glaucoma research.